rheumatoid immune disease with osteoporosis or low bone mass
Conditions
Interventions
99Tc-MDP Group:99Tc-MDP
Sponsors
Leshan People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects must provide informed consent and voluntarily sign the informed consent form prior to any research procedure; 2. The age of the subjects is greater than or equal to 18 years old; 3. A definite diagnosis of rheumatic immune disease, the type of disease is not limited but should be consistent with the diagnosis of rheumatic immune disease; 4. There is no limit to the duration of the included patients; 5. The peak bone loss of subjects detected by dual energy X-ray absorptiometry is less than -1.0 standard deviation; 6. Subjects with normal or good liver and kidney function (ALT<2ULN; normal creatinine); 7. The subjects had stable routine medication within 4 weeks before administration, and had no other serious comorbidities (tumor); 8. During the study, the patient is willing and able to follow the study protocol and has high compliance.
Exclusion criteria
Exclusion criteria: 1. Intravenous bisphosphonates have been used within 3 months before administration; 2.WBC<4x10^9/L or PLT<100x10^9/L; 3. Hypertension patients with cardiac insufficiency or difficult to control with conventional drugs; 4. Have a history of allergy to bisphosphonates; 5. Epilepsy and other nervous system disorders; 6. Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total procollagen type I amino-terminal propeptide;ß-collagen specific sequence;N-terminal-osteocalcin; | — |
Secondary
| Measure | Time frame |
|---|---|
| pain;Rheumatoid Arthritis Disease Activity;patient health assessment;Bath Ankylosing Spondylitis Disease Activity Index;Ankylosing Spondylitis Functional Index;Knee function score;Overall patient evaluation;Doctor's overall rating; | — |
Countries
China
Contacts
Public ContactWang Yan
Leshan People's Hospital
Outcome results
None listed